Skip to content

EMBRACE-OBS: Single-Site Observational Registry of Patient-Reported Outcomes Following MMA Embolization for Migraine

Enduring Migraine Benefit From Responsive Artery Coil Embolization - Observational (EMBRACE-OBS): A Single-Site Registry of Patient-Reported Outcomes Following Routine Clinical Care for Migraine

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07652034
Acronym
EMBRACE-OBS
Enrollment
50
Registered
2026-06-16
Start date
2026-07-01
Completion date
2028-06-01
Last updated
2026-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Migraine Headache, Migraine, Migraine Disorders

Keywords

Middle Meningeal Artery Embolization, MMA Embolization, Migraine, Headache, Patient-Reported Outcomes, HIT-6, Observational Registry, Neurointervention, EMBRACE-OBS

Brief summary

EMBRACE-OBS is the first phase of the EMBRACE research program. This single-site observational registry accesses and analyzes patient-reported outcome data already collected through routine clinical care from adults with migraine who have undergone or plan to undergo middle meningeal artery (MMA) embolization. The study describes changes in headache frequency, headache severity, medication use, migraine-related disability, quality of life, and reported adverse events over time without influencing clinical care.

Detailed description

EMBRACE-OBS is the first phase of the EMBRACE research program and is conducted as a single-site observational registry at Cortex Neurovascular. Migraine is a prevalent neurological disorder that can significantly affect quality of life and daily functioning. Middle meningeal artery (MMA) embolization is performed using FDA-cleared embolic devices. When used for migraine, the procedure is performed at the discretion of the treating physician as part of routine clinical care and independent of research participation. The purpose of this registry is to access and analyze clinical and patient-reported outcome data already collected through routine clinical care in patients who have undergone or plan to undergo MMA embolization for migraine. The study does not influence clinical decision-making, procedural technique, device selection, or follow-up care. The primary objective is to describe changes in patient-reported headache frequency and severity over time following MMA embolization performed as part of routine clinical care. Secondary objectives include describing changes in acute headache medication use, migraine-related disability, quality-of-life measures, medication use patterns, temporal patterns of symptom change, and the real-world safety profile of the procedure as reflected by reported adverse events and complications. Patient follow-up occurs through routine clinical care. Data accessed for this registry may include headache diaries, HIT-6 scores, clinical information, procedural information, medication use, and outcomes documented during routine clinical follow-up visits. No study-mandated interventions, procedures, visits, or assessments are performed. The research activity consists solely of accessing and analyzing information already documented during routine care. EMBRACE-OBS is conducted under a separate IRB-approved protocol (Solutions IRB Study 2026-Jun-1013). A separate interventional phase of the EMBRACE research program (EMBRACE-Full; NCT07313800) may be conducted in the future under appropriate regulatory approvals.

Interventions

Middle meningeal artery (MMA) embolization performed as part of routine clinical care at the discretion of the treating physician. The procedure is independent of study participation and is not assigned by the study protocol. The research activity consists solely of accessing and analyzing data already documented through routine clinical care.

Sponsors

Cortex Neurovascular
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
No

Inclusion criteria

* Adults aged 18 to 64 years * Diagnosis of migraine * Have undergone or plan to undergo middle meningeal artery (MMA) embolization as part of routine clinical care, independent of study participation * Able and willing to provide informed consent * Able to read and understand English sufficiently to complete informed consent and patient-reported outcome assessments

Exclusion criteria

* Age under 18 years * Pregnancy at the time of enrollment * Inability to provide informed consent * Inability to read and understand English sufficiently to complete informed consent and patient-reported outcome assessments * Insufficient clinical or patient-reported outcome data for the planned analyses

Design outcomes

Primary

MeasureTime frameDescription
Change in Patient-Reported Headache FrequencyBaseline and 12 MonthsChange in patient-reported headache frequency, measured as headache days per month, from baseline to 12 months following middle meningeal artery (MMA) embolization performed as part of routine clinical care.

Secondary

MeasureTime frameDescription
Change in HIT-6 ScoreBaseline and 12 MonthsChange in migraine-related disability as assessed by the Headache Impact Test (HIT-6) score (range: 36-78; higher scores indicate greater headache impact/worse outcome) documented during routine clinical care.

Countries

United States

Contacts

CONTACTDennis Wang, Principal Investigator, MD
dwang@cortexmgmt.com253-284-0841

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 19, 2026